




Certificate of Mailing (37 C.F.R. §1.8):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
First Class Mail in an envelope addressed to:
Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450
on this 19th day of November 2003.

s/ 
Julie Agozino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
TERO AHOLA ET. AL.

Serial No.: 10/688,648

Confirmation No.: TBA

Filed: October 17, 2003

For: PHARMACEUTICAL

Group Art Unit: TBA

Examiner: TBA

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the documents listed on the attached substitute Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified in 37 CFR 1.97(b)-i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.

It is respectfully requested that the Examiner confirm consideration of the cited documents by initialing the attached substitute Form PTO-1449 and returning a copy of the initialed form to the Applicant.

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 CFR 1.17(p) in the event that the period specified in 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 500329.

Respectfully submitted,

Date: Nov. 19, 2003

Keith D. Hutchinson
Keith D. Hutchinson
Attorney For Applicant
Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 526-4608
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.


Substitute for form 1449/PTO

Complete if Known

Application Number	10/688,648
Filing Date	October 17, 2003
First Named Inventor	Tero Ahola
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC25479A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER Number-Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	2002/0142940	10-03-2002	Barney Scott Graham, et al	
	AB	60/432,789	12-11-2002	Pfizer, Inc.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AC	EP 0672192	09-20-1995	Jeffrey S. Glen		
	AD	WO 00/47196	08-17-2000	Hollis-Eden Pharmaceuticals, Inc.		
	AE	UK 0224680.9	10-23-2002	Pfizer Limited		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AF	BARTENSCHLAGER, et. al., "Replication of Hepatitis C Virus," <i>Journal of General Virology</i> , 2000, 1631-1648, Vol 81.	
	AG	BISCHOFF, et. al., "Cerivastatin: Pharmacology of a Novel Synthetic and Highly Active HMG-CoA Reductase Inhibitor," <i>Atherosclerosis</i> , 1997, 119-130, Vol. 135.	
	AH	BISCHOFF, et. al., "Preclinical Review of Cerivastatin Sodium-a Step Forward in HMG-CoA Reductase Inhibition," <i>Atherosclerosis</i> , 1998, 139, Suppl. 1:S7-13.	
	AI	BLACK, "An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG - CoA Reductase Inhibitor," <i>Arch. Intern. Med.</i> , 1998, 577-584, Vol. 158.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.


Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

C mpl te if Known

Application Number	10/688,648
Filing Date	October 17, 2003
First Named Inventor	Tero Ahola
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC25479A



AJ	FICHTENBAUM, et. al., "Pharmacokinetic Interactions Between Protease Inhibitors and Statins in HIV Seronegative Volunteers: ACTG Study A5047," <i>Aids</i> , 2002, 569-577, Vol. 16, No. 4.
AK	GLENN, et. al., "Use of a Prenylation Inhibitor as a Novel Antiviral Agent," <i>Journal of Virology</i> , 1998, 9303-9306, Vol. 72, No. 11.
AL	GOWER, ET. AL., "Antiviral Activity of Lovastatin Against Respiratory Syncytial Virus In Vivo and In Vitro," <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 1231-1237, Vol. 45, No. 4.
AM	JAKOBISIAK, "Cell Cycle-Specific Effects of Lovastatin," <i>Proc. Natl. Acad. Sci.</i> , 1991, 3628-3632, Vol. 88.
AN	KRIEGER, et. al., "Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations," <i>Journal of Virology</i> , 2001, 4614-4624, Vol. 75, No. 10.
AO	LOHMANN, "Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line," <i>Science</i> , 1999, 110-113, Vol. 285.
AP	PEDERSEN, "Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease," <i>Drug Safety</i> , 1996, 11-24, Vol. 14.
AQ	PIETSCHMANN, et. al., "Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs," <i>Journal of Virology</i> , 2001, 1252-1264, Vol. 75, No. 3.
AR	ZEIN, Z. N., "Clinical Significance of Hepatitis C Virus Genotypes," <i>Clinical Microbiology Reviews</i> , 2000, 223-235, Vol. 13, No. 2.
AS	ZHANG and Casey, "Protein Prenylation: Molecular Mechanisms and Functional Consequences," <i>Ann. Rev. Biochem.</i> , 1996, 241-269, Vol. 65.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.